Hua Medicine

4:45 PM - 5:00 PM, Wednesday, June 5, 2019 ・ Theater 1
Hua Medicine is a China-based drug development company currently focused on developing a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 Diabetes (T2D). Dorzagliatin is a fourth generation glucokinase activator, originated at Roche AG, and in-licensed by Hua Medicine as a pre-clinical stage compound. Hua Medicine retains its global rights. Founded and funded by well-known and highly experienced US and China biotech specialists, including our founder and CEO, Dr. Li Chen (the former Chief Scientific Officer of Roche China), Hua Medicine is comprised of a team with extensive experience in global pharmaceutical research and development, and a portfolio advisory board comprised of some of the industry’s most significant key opinion leaders, academics, and scientists.
Ticker:
2552
Exchange:
HKEX
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
China
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
Dorzagliatin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CFO
Hua Medicine